{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:36:06Z","timestamp":1791347766342,"version":"4.3.1"},"reference-count":78,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bone"],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1016\/j.bone.2009.08.053","type":"journal-article","created":{"date-parts":[[2009,9,3]],"date-time":"2009-09-03T08:56:27Z","timestamp":1251968187000},"page":"49-63","source":"Crossref","is-referenced-by-count":181,"title":["A physiologically based mathematical model of integrated calcium homeostasis and bone remodeling"],"prefix":"10.1016","volume":"46","author":[{"given":"Mark C.","family":"Peterson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew M.","family":"Riggs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2009.08.053_bib1","doi-asserted-by":"crossref","first-page":"4330","DOI":"10.1210\/jc.2002-011870","article-title":"A minimal mathematical model of calcium homeostasis","volume":"87","author":"Raposo","year":"2002","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2009.08.053_bib2","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jtbi.2004.03.023","article-title":"Modeling the interactions between osteoblast and osteoclast activities in bone remodeling","volume":"229","author":"Lemaire","year":"2004","journal-title":"J. Theor. Biol."},{"key":"10.1016\/j.bone.2009.08.053_bib3","doi-asserted-by":"crossref","first-page":"50259","DOI":"10.1074\/jbc.M307444200","article-title":"Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism","volume":"278","author":"Bellido","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bone.2009.08.053_bib4","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/BF02584211","article-title":"Systems analysis of arterial pressure regulation and hypertension","volume":"1","author":"Guyton","year":"1972","journal-title":"Ann. Biomed. Eng."},{"key":"10.1016\/j.bone.2009.08.053_bib5","series-title":"Forteo\u00ae teriparitide (rDNA origin) injection package insert","first-page":"1","year":"2004"},{"key":"10.1016\/j.bone.2009.08.053_bib6","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1056\/NEJMoa044459","article-title":"Denosumab in postmenopausal women with low bone mineral density","volume":"354","author":"McClung","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2009.08.053_bib7","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1359\/jbmr.070809","article-title":"Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD","volume":"22","author":"Lewiecki","year":"2007","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2009.08.053_bib8","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1046\/j.1523-1755.1999.00617.x","article-title":"Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure","volume":"56","author":"Rix","year":"1999","journal-title":"Kidney Int."},{"key":"10.1016\/j.bone.2009.08.053_bib9","series-title":"Pharmacokinetics","author":"Gibaldi","year":"1982"},{"key":"10.1016\/j.bone.2009.08.053_bib10","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1530\/eje.0.1420451","article-title":"Immediate changes in biochemical markers of bone turnover and circulating interleukin-6 after parathyroidectomy for primary hyperparathyroidism","volume":"142","author":"Guo","year":"2000","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.bone.2009.08.053_bib11","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1210\/jc.2004-0842","article-title":"Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism","volume":"90","author":"Peacock","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2009.08.053_bib12","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1056\/NEJMoa050336","article-title":"One year of alendronate after one year of parathyroid hormone (1\u201384) for osteoporosis","volume":"353","author":"Black","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2009.08.053_bib13","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1210\/er.2004-0006","article-title":"Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use","volume":"26","author":"Hodsman","year":"2005","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.bone.2009.08.053_bib14","article-title":"RANKL and OPG regulation of bone remodeling in health and disease","author":"Kearns","year":"2007","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.bone.2009.08.053_bib15","first-page":"24","article-title":"A population PK\/PD model describes the rapid, profound, and sustained suppression of urinary N-telopeptide following administration of AMG 162, a fully human monoclonal antibody against RANKL, to healthy postmenopausal women","author":"Peterson","year":"2004","journal-title":"AAPS J."},{"key":"10.1016\/j.bone.2009.08.053_bib16","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1080\/07315724.2003.10719287","article-title":"Calcium absorption varies within the reference range for serum 25-hydroxyvitamin D","volume":"22","author":"Heaney","year":"2003","journal-title":"J. Am. Coll. Nutr."},{"key":"10.1016\/j.bone.2009.08.053_bib17","first-page":"4111","article-title":"Calcium absorptive effects of vitamin D and its major metabolites","volume":"82","author":"Heaney","year":"1997","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2009.08.053_bib18","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1093\/ajcn\/80.4.998","article-title":"Effect of age on calcium absorption in postmenopausal women","volume":"80","author":"Nordin","year":"2004","journal-title":"Am. J. Clin. Nutr"},{"key":"10.1016\/j.bone.2009.08.053_bib19","first-page":"4023","article-title":"Relationship of intestinal calcium absorption to 1,25-dihydroxyvitamin D [1,25(OH)2D] levels in young versus elderly women: evidence for age-related intestinal resistance to 1,25(OH)2D action","volume":"85","author":"Pattanaungkul","year":"2000","journal-title":"J. Clin. Endocrinol. Metab"},{"key":"10.1016\/j.bone.2009.08.053_bib20","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1093\/ajcn\/72.2.466","article-title":"Factors associated with calcium absorption efficiency in pre- and perimenopausal women","volume":"72","author":"Wolf","year":"2000","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.bone.2009.08.053_bib21","first-page":"130","article-title":"In vivo intestinal absorption of calcium in humans","volume":"16","author":"Sheikh","year":"1990","journal-title":"Miner. Electrolyte. Metab."},{"key":"10.1016\/j.bone.2009.08.053_bib22","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1093\/jn\/132.11.3428","article-title":"Passive diffusion does not play a major role in the absorption of dietary calcium in normal adults","volume":"132","author":"McCormick","year":"2002","journal-title":"J. Nutr."},{"key":"10.1016\/j.bone.2009.08.053_bib23","series-title":"Physiology and pharmacology of bone","first-page":"1","article-title":"Calcium homeostasis","author":"Parfitt","year":"1993"},{"key":"10.1016\/j.bone.2009.08.053_bib24","series-title":"Calcium, phosphate and magnesium: clinical physiology and diagnostic procedures","author":"Nordin","year":"1976"},{"key":"10.1016\/j.bone.2009.08.053_bib25","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.bone.2005.04.036","article-title":"Bone as an ion exchange organ: evidence for instantaneous cell-dependent calcium efflux from bone not due to resorption","volume":"37","author":"Marenzana","year":"2005","journal-title":"Bone"},{"key":"10.1016\/j.bone.2009.08.053_bib26","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/BF02353861","article-title":"A non-Markovian model for calcium kinetics in the body","volume":"22","author":"Weiss","year":"1994","journal-title":"J. Pharmacokinet. Biopharm."},{"key":"10.1016\/j.bone.2009.08.053_bib27","doi-asserted-by":"crossref","first-page":"F1005","DOI":"10.1152\/ajprenal.00420.2004","article-title":"RANK ligand and TNF-alpha mediate acid-induced bone calcium efflux in vitro","volume":"289","author":"Frick","year":"2005","journal-title":"Am. J. Physiol. Renal. Physiol."},{"key":"10.1016\/j.bone.2009.08.053_bib28","first-page":"680","article-title":"Renal excretion of calcium in man: estimation of Tm-Ca","volume":"9","author":"Copp","year":"1960","journal-title":"Metabolism"},{"key":"10.1016\/j.bone.2009.08.053_bib29","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/jcp.21.3.353","article-title":"Tubular reabsorption of calcium in normal and hypercalciuric subjects","volume":"21","author":"Peacock","year":"1968","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.bone.2009.08.053_bib30","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/S0140-6736(69)90813-7","article-title":"Role of kidney in regulation of plasma-calcium","volume":"2","author":"Nordin","year":"1969","journal-title":"Lancet"},{"key":"10.1016\/j.bone.2009.08.053_bib31","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1152\/physrev.00003.2004","article-title":"Calcium absorption across epithelia","volume":"85","author":"Hoenderop","year":"2005","journal-title":"Physiol. Rev"},{"key":"10.1016\/j.bone.2009.08.053_bib32","first-page":"4236","article-title":"Control of pulsatile and tonic parathyroid hormone secretion by ionized calcium","volume":"81","author":"Schmitt","year":"1996","journal-title":"J Clin. Endocrinol. Metab"},{"key":"10.1016\/j.bone.2009.08.053_bib33","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1210\/jcem-56-3-572","article-title":"Four-parameter model of the sigmoidal relationship between parathyroid hormone release and extracellular calcium concentration in normal and abnormal parathyroid tissue","volume":"56","author":"Brown","year":"1983","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2009.08.053_bib34","first-page":"1489","article-title":"Direct in vivo comparison of calcium-regulated parathyroid hormone secretion in normal volunteers and patients with secondary hyperparathyroidism","volume":"76","author":"Ramirez","year":"1993","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2009.08.053_bib35","first-page":"2765","article-title":"Calcium-sensing by parathyroid glands in secondary hyperparathyroidism","volume":"83","author":"Goodman","year":"1998","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2009.08.053_bib36","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1093\/ndt\/14.10.2398","article-title":"The PTH\u2013calcium curve and the set point of calcium in primary and secondary hyperparathyroidism","volume":"14","author":"Malberti","year":"1999","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.bone.2009.08.053_bib37","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1038\/ki.1996.483","article-title":"Non-suppressible parathyroid hormone secretion is related to gland size in uremic secondary hyperparathyroidism","volume":"50","author":"Indridason","year":"1996","journal-title":"Kidney Int."},{"key":"10.1016\/j.bone.2009.08.053_bib38","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1053\/ajkd.2001.20740","article-title":"Role of phosphorus in the pathogenesis of secondary hyperparathyroidism","volume":"37","author":"Slatopolsky","year":"2001","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.bone.2009.08.053_bib39","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1046\/j.1523-1755.2002.00265.x","article-title":"Hyperplasia of the parathyroid gland without secondary hyperparathyroidism","volume":"61","author":"Takahashi","year":"2002","journal-title":"Kidney Int."},{"issue":"Suppl 3","key":"10.1016\/j.bone.2009.08.053_bib40","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/ndt\/13.suppl_3.3","article-title":"The role of calcium, phosphorus and vitamin D metabolism in the development of secondary hyperparathyroidism","volume":"13","author":"Slatopolsky","year":"1998","journal-title":"Nephrol. Dial. Transplant."},{"issue":"Suppl 3","key":"10.1016\/j.bone.2009.08.053_bib41","first-page":"iii47","article-title":"Efficacy of direct injection of calcitriol into the parathyroid glands in uraemic patients with moderate to severe secondary hyperparathyroidism","volume":"18","author":"Nakanishi","year":"2003","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.bone.2009.08.053_bib42","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1038\/ki.1994.223","article-title":"Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD","volume":"45","author":"Quarles","year":"1994","journal-title":"Kidney Int."},{"key":"10.1016\/j.bone.2009.08.053_bib43","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1093\/clinchem\/48.10.1731","article-title":"Kinetic analyses of parathyroid hormone clearance as measured by three rapid immunoassays during parathyroidectomy","volume":"48","author":"Bieglmayer","year":"2002","journal-title":"Clin. Chem."},{"key":"10.1016\/j.bone.2009.08.053_bib44","unstructured":"Deftos L. Chapter 2. Calcium and phosphate homeostasis. In: Diseases of bone and mineral metabolism. Endotext.org."},{"key":"10.1016\/j.bone.2009.08.053_bib45","series-title":"Section I: Disorders of water, electrolytes, and acid-base:","article-title":"Chapter 7. Disorders of phosphate balance","author":"Levi","year":"2008"},{"key":"10.1016\/j.bone.2009.08.053_bib46","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(75)92736-1","article-title":"Nomogram for derivation of renal threshold phosphate concentration","volume":"2","author":"Walton","year":"1975","journal-title":"Lancet"},{"key":"10.1016\/j.bone.2009.08.053_bib47","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1210\/jcem.85.3.6456","article-title":"Close correlation between estrogen treatment and renal phosphate reabsorption capacity","volume":"85","author":"Uemura","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2009.08.053_bib48","doi-asserted-by":"crossref","first-page":"E430","DOI":"10.1152\/ajpendo.00140.2004","article-title":"Effects of endogenous estrogen on renal calcium and phosphate handling in elderly women","volume":"288","author":"Dick","year":"2005","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2009.08.053_bib49","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S1297-319X(01)00274-3","article-title":"Phosphate, the renal tubule, and the musculoskeletal system","volume":"68","author":"Laroche","year":"2001","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.bone.2009.08.053_bib50","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1172\/JCI104064","article-title":"Protein-binding of inorganic phosphate in plasma of normal subjects and patients with renal disease","volume":"39","author":"Walser","year":"1960","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bone.2009.08.053_bib51","doi-asserted-by":"crossref","first-page":"44975","DOI":"10.1074\/jbc.M303905200","article-title":"Transforming growth factor-beta controls human osteoclastogenesis through the p38 MAPK and regulation of RANK expression","volume":"278","author":"Karsdal","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bone.2009.08.053_bib52","doi-asserted-by":"crossref","first-page":"48868","DOI":"10.1074\/jbc.M208494200","article-title":"Parathyroid hormone stimulates receptor activator of NFkappa B ligand and inhibits osteoprotegerin expression via protein kinase A activation of cAMP-response element-binding protein","volume":"277","author":"Fu","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bone.2009.08.053_bib53","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1210\/endo.142.9.8356","article-title":"Catabolic effects of continuous human PTH (1\u201338) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation","volume":"142","author":"Ma","year":"2001","journal-title":"Endocrinology"},{"key":"10.1016\/j.bone.2009.08.053_bib54","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.1210\/en.2005-0239","article-title":"Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis","volume":"146","author":"Bellido","year":"2005","journal-title":"Endocrinology"},{"key":"10.1016\/j.bone.2009.08.053_bib55","doi-asserted-by":"crossref","first-page":"12854","DOI":"10.1074\/jbc.M313294200","article-title":"Smurf1 inhibits osteoblast differentiation and bone formation in vitro and in vivo","volume":"279","author":"Zhao","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bone.2009.08.053_bib56","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1359\/jbmr.070518","article-title":"Quantifying osteoblast and osteocyte apoptosis: challenges and rewards","volume":"22","author":"Jilka","year":"2007","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2009.08.053_bib57","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1074\/jbc.M106339200","article-title":"Expression of the osteoblast differentiation factor RUNX2 (Cbfa1\/AML3\/Pebp2alpha A) is inhibited by tumor necrosis factor-alpha","volume":"277","author":"Gilbert","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bone.2009.08.053_bib58","doi-asserted-by":"crossref","first-page":"6815","DOI":"10.1016\/S0021-9258(17)37449-5","article-title":"Characterization and autoregulation of latent transforming growth factor beta (TGF beta) complexes in osteoblast-like cell lines. Production of a latent complex lacking the latent TGF beta-binding protein","volume":"269","author":"Dallas","year":"1994","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bone.2009.08.053_bib59","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1210\/er.2004-0001","article-title":"Transforming growth factor-beta1 to the bone","volume":"26","author":"Janssens","year":"2005","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.bone.2009.08.053_bib60","doi-asserted-by":"crossref","first-page":"21352","DOI":"10.1074\/jbc.M111663200","article-title":"Proteolysis of latent transforming growth factor-beta (TGF-beta)-binding protein-1 by osteoclasts. A cellular mechanism for release of TGF-beta from bone matrix","volume":"277","author":"Dallas","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bone.2009.08.053_bib61","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1083\/jcb.124.1.171","article-title":"Latent transforming growth factor-beta 1 associates to fibroblast extracellular matrix via latent TGF-beta binding protein","volume":"124","author":"Taipale","year":"1994","journal-title":"J. Cell. Biol."},{"key":"10.1016\/j.bone.2009.08.053_bib62","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1359\/jbmr.2001.16.10.1787","article-title":"Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions","volume":"16","author":"Quinn","year":"2001","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2009.08.053_bib63","doi-asserted-by":"crossref","first-page":"44061","DOI":"10.1074\/jbc.M207205200","article-title":"Matrix metalloproteinase-dependent activation of latent transforming growth factor-beta controls the conversion of osteoblasts into osteocytes by blocking osteoblast apoptosis","volume":"277","author":"Karsdal","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bone.2009.08.053_bib64","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1359\/jbmr.1998.13.5.793","article-title":"Osteoblast programmed cell death (apoptosis): modulation by growth factors and cytokines","volume":"13","author":"Jilka","year":"1998","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2009.08.053_bib65","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1359\/jbmr.2001.16.6.975","article-title":"Osteoblast apoptosis and bone turnover","volume":"16","author":"Hock","year":"2001","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2009.08.053_bib66","unstructured":"FDA, CDER. Forteo summary basis of approval. Forteo [teriparatide (rDNA origin)] injection. Company: Eli Lilly and Company. Application No. 021318. Approval Date: 11\/26\/2002. In; 2002."},{"key":"10.1016\/j.bone.2009.08.053_bib67","doi-asserted-by":"crossref","first-page":"5592","DOI":"10.1210\/en.2006-0459","article-title":"Glucocorticoids act directly on osteoclasts to increase their life span and reduce bone density","volume":"147","author":"Jia","year":"2006","journal-title":"Endocrinology"},{"key":"10.1016\/j.bone.2009.08.053_bib68","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1210\/edrv.20.3.0367","article-title":"Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families","volume":"20","author":"Suda","year":"1999","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.bone.2009.08.053_bib69","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1359\/JBMR.050105","article-title":"Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis","volume":"20","author":"Chen","year":"2005","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2009.08.053_bib70","unstructured":"Food US, Drug A, Center for Drug E, Research. Forteo summary basis of approval. Forteo [teriparatide (rDNA origin)] injection. Company: Eli Lilly and Company. Application No. 021318. Approval Date: 11\/26\/2002. In; 2002."},{"key":"10.1016\/j.bone.2009.08.053_bib71","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1172\/JCI110372","article-title":"Short-term effects of synthetic human parathyroid hormone-(1\u201334) administration on bone mineral metabolism in osteoporotic patients","volume":"68","author":"Slovik","year":"1981","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bone.2009.08.053_bib72","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1056\/NEJM199910213411701","article-title":"A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery","volume":"341","author":"Silverberg","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2009.08.053_bib73","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/BF00441552","article-title":"Biochemical markers of bone turnover, intact serum parathyroid horn and renal calcium excretion in patients with pseudohypoparathyroidism and hypoparathyroidism before and during vitamin D treatment","volume":"148","author":"Kruse","year":"1989","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.bone.2009.08.053_bib74","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.bone.2005.04.011","article-title":"Response to continuous and pulsatile PTH dosing: a mathematical model for parathyroid hormone receptor kinetics","volume":"37","author":"Potter","year":"2005","journal-title":"Bone"},{"key":"10.1016\/j.bone.2009.08.053_bib75","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1006\/bulm.1999.0146","article-title":"Parathyroid hormone temporal effects on bone formation and resorption","volume":"62","author":"Kroll","year":"2000","journal-title":"Bull. Math. Biol."},{"key":"10.1016\/j.bone.2009.08.053_bib76","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0303-2647(03)00040-6","article-title":"Modeling of bone formation and resorption mediated by parathyroid hormone: response to estrogen\/PTH therapy","volume":"70","author":"Rattanakul","year":"2003","journal-title":"Biosystems"},{"key":"10.1016\/j.bone.2009.08.053_bib77","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1210\/en.2004-1642","article-title":"Mathematical model of paracrine interactions between osteoclasts and osteoblasts predicts anabolic action of parathyroid hormone on bone","volume":"146","author":"Komarova","year":"2005","journal-title":"Endocrinology"},{"key":"10.1016\/j.bone.2009.08.053_bib78","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.bone.2008.03.025","article-title":"Model structure and control of bone remodeling: a theoretical study","volume":"43","author":"Pivonka","year":"2008","journal-title":"Bone"}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328209018821?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328209018821?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,10,10]],"date-time":"2021-10-10T05:45:25Z","timestamp":1633844725000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328209018821"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1]]},"references-count":78,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["S8756328209018821"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2009.08.053","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2010,1]]}}}